Facing the COVID-19 global healthcare crisis, scientists worldwide are 
collaborating to develop prophylactic and therapeutic interventions against the 
disease. Antibody therapeutics hold enormous promise for the treatment of 
COVID-19. In March 2020, the Chinese Antibody Society, in collaboration with The 
Antibody Society, initiated the "COVID-19 Antibody Therapeutics Tracker" 
("Tracker") (https://chineseantibody.org/covid-19-track/) program to track the 
antibody-based COVID-19 interventions in preclinical and clinical development 
globally. The data are collected from the public domain and verified by 
volunteers on an ongoing basis. Here, we present exploratory data analyses and 
visualization to demonstrate the latest trends of COVID-19 antibody development, 
based on data for over 150 research and development programs and molecules 
included in the "Tracker" as of 8 August 2020. We categorized the data mainly by 
their targets, formats, development status, developers and country of origin. 
Although details are limited in some cases, all of the anti-SARS-CoV-2 antibody 
candidates appear to target the viral spike protein (S protein), and most are 
full-length monoclonal antibodies. Most of the current COVID-19 antibody 
therapeutic candidates in clinical trials are repurposed drugs aimed at targets 
other than virus-specific proteins, while most of these virus-specific 
therapeutic antibodies are in discovery or preclinical studies. As of 8 August 
2020, eight antibody candidates targeting the SARS-CoV-2 S protein have entered 
clinical studies, including LY-CoV555, REGN-COV2, JS016, TY027, CT-P59, 
BRII-196, BRII-198 and SCTA01. Ongoing clinical trials of SARS-CoV-2 
neutralizing antibodies will help define the utility of these antibodies as a 
new class of therapeutics for treating COVID-19 and future coronavirus 
infections.